Close Menu

HIV-1 infection

A Reduction Grade of Lipodystrophy and Limited Side Effects after HAART Regimen with Raltegravir, Lamivudine, Darunavir and Ritonavir in an HIV-1 Infected Patient after Six Years of Antiretroviral Therapy

Issue: 
DOI: 
10.7727/wimj.2014.066
Pages: 
291–3

ABSTRACT

Accepted: 
14 Apr, 2015
PDF Attachment: 
Journal Sections: 
e-Published: 14 Jul, 2015

Long-term Maraviroc Therapy and Limited Side Effects in an HIV-1 Experienced Patient: Six Years of Antiretroviral Observation

Issue: 
DOI: 
10.7727/wimj.2014.068
Pages: 
785–7
 
INTRODUCTION
 
Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. This drug, classed as an entry inhibitor, was developed by the drug company Pfizer in its United Kingdom laboratory located in Sandwich. 
 
Accepted: 
27 Mar, 2014
PDF Attachment: 
Journal Sections: 
e-Published: 29 Aug, 2014
Subscribe to RSS - HIV-1 infection
Top of Page